الفهرس 
Formulation and evaluation of certain drug delivery systems for wound healing
List of contentsOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
Wound healing is still an unmet challenge amongst surgical society. Wounds might be lethal in numerous incidents especially those presented by burns, chronic diseases, and post-operative trauma, as they may be readily colonized by microbes and resistant bacteria. Many biomaterials were developed as means to generate a proper area for tissue regeneration and perform as a suitable barrier against wound infection.Wound healing is a complex biological process consisting of healing of both dermal and epidermal tissues via their regeneration. It includes a sequence of different phases including, inflammation, migration, proliferation, maturation, and/or remodeling.
Numerous wound biomaterials are generally loaded up with antimicrobials to perform against contagious microorganisms and avoid undesirable events such as bacteremia and sepsis. Topical antibiotics play an essential role in treating and preventing abundant dermal bacterial infections due to abrasion, injury, and surgery. Linezolid (LNZ) is a synthetic oxazolidinone antibiotic that has been approved by the Food and Drug Administration (FDA) for the treatment of wound pathogens initiated by Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), penicillin-resistant Streptococcus pneumoniaand glycopeptideintermediate Staphylococcus aureus (GISA). LNZ inhibits the protein synthesis via attaching to the 50S ribosomal subunit, therefore obstructing bacterial growth.